Holen Sie sich die Stockscreener-App
24.32
1.84%
0.44
Handel nachbörslich:
24.34
0.02
+0.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$23.88
Offen:
$24.15
24-Stunden-Volumen:
52.23M
Relative Volume:
1.34
Marktkapitalisierung:
$138.61B
Einnahmen:
$63.32B
Nettoeinkommen (Verlust:
$7.52B
KGV:
18.65
EPS:
1.3043
Netto-Cashflow:
$9.48B
1W Leistung:
+2.75%
1M Leistung:
-4.81%
6M Leistung:
-3.42%
1J Leistung:
-3.95%
1-Tages-Spanne:
$24.13
$24.57
1-Wochen-Bereich:
$23.74
$24.57
52-Wochen-Spanne:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.32 | 137.24B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,213.91 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.04 | 611.36B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
261.07 | 444.60B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.56 | 317.37B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.90 | 299.04B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer CEO on primary care, GLP-1 outlook and innovation timeline - AOL.com
Form 4 Pfizer For: 1 July By Investing.com - Investing.com Canada
Pfizer Inc. focuses on long-term therapies as investors watch the stock - AD HOC NEWS
Can Pfizer (NYSE:PFE) Advance Its Next-Generation Oncology Pipeline? - Kalkine Media
Pfizer Expands Migraine Strategy With New Rimegepant Redosing Study - TipRanks
Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy? - Yahoo Finance
June Social Media Round-Up—2025 Impact Report, ADA 2026, and More - Pfizer
Is Pfizer (PFE) Stock Undervalued Despite Mixed Oncology Progress? - Yahoo Finance
Nike Appoints Pfizer CFO as New Finance Chief Amid Industry Experience Questions - marketscreener.com
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Pfizer Inc. stock outperforms competitors despite losses on the day - MarketWatch
Pfizer (NYSE:PFE) yield tops 7% after stock falls on China GLP-1 news - TechStock²
Form 4 Pfizer For: 30 June By Investing.com - Investing.com Canada
Pfizer-BioNTech COVID-19 Vaccine from Pfizer Inc.mRNA shot anchoring US immunization plans - AD HOC NEWS
Why Pfizer Could Prove to Be an Underrated GLP-1 Stock - The Globe and Mail
Pfizer Inc (NYSE:PFE) Reshapes Healthcare Pipeline Through Dealmaking - Kalkine Media
Pfizer opens the week with a clear earnings calendar, shares on NYSE in focus - AD HOC NEWS
Parasite Cleanse Market to See Booming Growth 2026-2033 | Bayer AG, Pfizer Inc., Merck & Co., Inc. - openPR.com
Big Pharma Has a Case of Merger Mania - The Motley Fool
The Paxlovid tablets from Pfizer Inc.antiviral course that fits into daily routine - AD HOC NEWS
Why Is Pfizer (NYSE:PFE) Catching Value Stock Attention? - Kalkine Media
PFE Stock Quote Price and Forecast - CNN
Will FDA’s New IBRANCE (palbociclib) Maintenance Approval Reshape Pfizer’s (PFE) Oncology Narrative? - simplywall.st
Pfizer, Innovent GLP-1 drugs clear China insurance hurdle - Reuters
Is Pfizer Inc. (PFE) A Good Stock To Buy Now? - Insider Monkey
Pfizer muted in pharma sector comparison, shares trail S&P 500 peers - AD HOC NEWS
Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review - Yahoo Finance
Pfizer’s CFO Just Left and a Key Drug Trial Missed. Here’s What That Means for PFE Stock in 2026 - TIKR.com
China surpassing Europe in Drug Innovation and Development, Pfizer Inc. (PFE) Executive says - Insider Monkey
Pfizer (NYSE:PFE) yield math back in focus after cancer drug miss, shares recover Friday - TechStock²
Pfizer (PFE) Could Be 13% Undervalued On Mixed Oncology News And CFO Change - simplywall.st
Pfizer Inc. - Encyclopedia Britannica
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now - The Motley Fool
Is Pfizer (NYSE:PFE) Building A Stronger Cancer Portfolio? - Kalkine Media
Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends - Yahoo Finance
Pfizer (PFE) Wins EU Approval For Keytruda And Padcev In Bladder Cancer - simplywall.st
Pfizer Beats Ex-Worker's Whistleblower Retaliation Suit - Law360
Prevnar 20 from Pfizer Inc.broader pneumococcal cover in one syringe - Ad-hoc-news.de
Pfizer Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Price to earnings forward of Pfizer Inc. – BCS:PFECL - TradingView
Why Did Pfizer (NYSE:PFE) Gain Attention After FDA Approval? - Kalkine Media
Pfizer: Why Being Bullish Makes Sense Despite The Patent Cliff (NYSE:PFE) - Seeking Alpha
Nike Names Pfizer’s Denton as Next CFO - WSJ
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer? - Yahoo Finance
A Big Pharma Executive Is Jumping to Nike—and Critics Are Already Questioning the Move - inc.com
Pfizer Discontinues Vizimpro In US Amid Oncologist Preference Shift - insights.citeline.com
Vitiligo Market to Witness Transformational Growth Opportunities by 2034 – DelveInsight | Pfizer, Clinuvel, Inc., Clinuvel Pharma, Bioniz Therapeutics, TAGCyx Biotech - Barchart.com
A Prostate Cancer Survivor Shares the Importance of Early Detection—and Why Knowing Your History, Monitoring PSA and Talking to Your Doctor Matters - Pfizer
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Dividend Roundup: Pfizer, AT&T, Comcast, Sysco, and more - Seeking Alpha
Pfizer (PFE) Wins New IBRANCE Use As Lung Cancer Trial Tests Its Pipeline - simplywall.st
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pfizer Inc-Aktie (PFE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SAHNI PAYAL | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
82,816 |
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
4.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):